AJP - Renal AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol (February 12, 2002). doi:10.1152/ajprenal.00317.2001
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/1/F190    most recent
00317.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peherstorfer, E.
Right arrow Articles by Oberbauer, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Peherstorfer, E.
Right arrow Articles by Oberbauer, R.

Articles in PresS, published online ahead of print February 12, 2002
Am J Physiol Renal Physiol, 10.1152/ajprenal.00317.2001
Submitted on October 23, 2001
Accepted on February 6, 2002

EFFECTS OF MICROINJECTION OF SYNTHETIC BCL-2 FAMILY MEMBER DOMAIN PEPTIDES ON APOPTOSIS OF RENAL TUBULAR EPITHELIAL CELLS

Elisabeth Peherstorfer1, Bernd Mayer2, Stefan Boehm3, Arno Lukas2, Peter Hauser1, Gert Mayer4, and Rainer Oberbauer1*

1 Department of Internal Medicine III, Division of Nephrology and Dialysis, University of Vienna, Vienna, Austria
2 Institute for Theoretical Chemistry and Molecular Structural Biology, University of Vienna, Vienna, Austria
3 Institute of Pharmacology, University of Vienna, Vienna, Austria
4 Division of Nephrology and Dialysis, University of Innsbruck, Innsbruck, Austria

* To whom correspondence should be addressed. E-mail: rainer.oberbauer{at}akh-wien.ac.at.

Bcl-2 protein family members are among the key regulators of the apoptosis effector phase. Therefore, we investigated the ability of synthetic peptides derived from proteins of the Bcl-2 family, namely the N-terminal region of Bcl-2 (Bcl2_syn), a central domain of Bax (Bax_syn), as well as central domain of Bak (Bak_syn) to interfere with the apoptotic process in LLC-PK1 cells. Apoptosis was induced by tacrolimus or LPS treatment, and microinjection of Bcl2_syn into stimulated LLC-PK1 cells significantly reduced the percentage of apoptotic cells detected within four hours after the treatment. Microinjection of Bax_syn or Bax_syn, in contrast, induced apoptosis in otherwise untreated LLC-PK1 cells during the same period of time. A random sequence control peptide (control_syn), which served as a negative control, as well as FITC-labeled dextran, which was co-injected in all experiments for visualization, were ineffective in either preventing or inducing apoptosis. These results suggest that synthetic peptides mimicking the functional domains of proteins of the Bcl-2 family are capable of regulating apoptosis when microinjected into LLC-PK1 cells in vivo. Analoga to these regulatory peptides could therefore provide valuable lead compounds in the therapeutical context.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
U. Vijapurkar, W. Wang, and R. Herbst
Potentiation of Kinesin Spindle Protein Inhibitor-Induced Cell Death by Modulation of Mitochondrial and Death Receptor Apoptotic Pathways
Cancer Res., January 1, 2007; 67(1): 237 - 245.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
B. Mayer and R. Oberbauer
Mitochondrial Regulation of Apoptosis
Physiology, June 1, 2003; 18(3): 89 - 94.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1976 by the American Physiological Society.